TMOのチャート
TMOの企業情報
| symbol | TMO |
|---|---|
| 会社名 | Thermo Fisher Scientific Inc （TMO サ―モ・フィッシャ―・サイエンティフィック） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 サーモ・フィッシャー・サイエンティフィック（Thermo Fisher Scientific Inc.）は各種製品の開発・製造・販売を行う。同社は分析機器、設備、試薬・消耗品、研究・製造・分析・発見・診断用ソフトウェアとサービスを提供する。同社は4つの事業区分により構成される。ライフ・サイエンス・ソリューション事業は試薬、機器、消耗品のポートフォリオを提供する。分析機器事業は各種機器、消耗品、ソフトウェア、サービスを提供する。スペシャリティ・ダイアグノスティックス事業は各種診断テスト・キット、試薬、培地、機器と関連製品を提供する。ラボ製品・サービス事業は温度制御技術製品、成長保護・分離製品、水と実験室製品を提供する。 サ―モ・フィッシャ―・サイエンティフィックは米国の科学関連サ―ビス企業。主に製薬会社、バイテク企業、学術・政府研究機関、臨床検査室に各種分析機器、ラボ自動化システム、分析デ―タ管理ソフトウエア、バイオサイエンス試薬、診断・検査キット、臨床検査管理、生物検体保管、分析テスト、サプライチェ―ン管理等のサ―ビスを提供。 Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Its Mission is to enable our customers to make the world healthier, cleaner and safer. Whether the customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, the company is here to support them. Its global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. |
| 本社所在地 | 781 622-1000 |
| 代表者氏名 | Jim P. Manzi |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 781-622-1000 |
| 設立年月日 | 20607 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 70000人 |
| url | www.thermofisher.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 6141.00000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 109215.30000 |
| 売上高 | 売上高（百万ドル） 24358.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 126071.30000 |
| 当期純利益 | 当期純利益（百万ドル） 2938.00000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Thermo Fisher Scientific Inc. revenues increased 16% to $24.36B. Net income before extraordinary items increased 21% to $2.94B. Revenues reflect Laboratory products and services segment increase of 28% to $10.04B Analytical Technologies segment increase of 13% to $5.47B Life Sciences Solutions segment increase of 9% to $6.27B Other segment increase of 18% to $10.23B. |
TMOのテクニカル分析
TMOのニュース
Single-Use Assemblies Global Market Report 2022: Ukraine-Russia War Impact 2022/12/09 10:00:00 PR Newswire
NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Major players in the single-use assemblies market are Avantor Inc., Corning Incorporated, Danaher Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Saint-Gobain, Parker Hannifin Corporation, Repligen Corporation, Newage…
Clinical Chemistry Global Market Report 2022: Ukraine-Russia War Impact 2022/12/09 09:30:00 PR Newswire
NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Major players in the clinical chemistry market are Abbott Laboratories, F. Hoffmann-La Roche Ltd., ELITech Group, Beckman Coulter Inc., Thermo Fisher Scientific Inc., Siemens AG, Ortho Clinical Diagnostics, Diatron Mi Apac Private Limited, Nova…
FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy 2022/12/07 14:29:19 GenomeWeb
The marketing authorization makes Thermo Fisher’s SeCore CDx HLA Sequencing System the first and so far only commercially available HLA typing companion diagnostic.
RBC Capital Starts Thermo Fisher Scientific at Outperform 2022/12/06 21:30:09 Investing.com
https://www.investing.com/news/pro/rbc-capital-starts-thermo-fisher-scientific-at-outperform-432SI-2958574
Thermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Net-zero Emissions 2022/12/06 13:00:00 Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a new 2030 greenhouse gas emissions reduction target to reduce its Scope 1 and 2 emissions from operations by more than 50% from a 2018 baseline.1 The company is on track to achieve its previous 2030 goal of a 30% reduction, ahead of schedule. The company’s new 50% reduction target fulfills its commitment to the Business Ambition to 1.5˚C campaign and aligns its clima
Top 5 3rd Quarter Trades of AKO CAPITAL LLP 2022/11/01 19:00:16 GuruFocus
Related Stocks: DEO , GOOG , TMO , MSFT , CHTR ,
Thermo Fisher Scientific PT Lowered to $665 at Baird 2022/11/01 11:05:15 Investing.com
https://www.investing.com/news/pro/thermo-fisher-scientific-pt-lowered-to-665-at-baird-432SI-2927901
Thermo Fisher to Acquire Binding Site For $2.6 Billion 2022/10/31 15:07:51 TipRanks
Thermo Fisher Scientific (NYSE: TMO), the supplier of scientific instrumentation, announced on Monday that it will acquire The Binding Site Group, a specialty diagnostics company headquartered in Birmingham, UK for $2.6 billion. Thermo Fisher will acquire Binding Site from a shareholder group led by private equity firm Nordic Capital. Binding Site''s business has been growing by around 10% every year and is on track to deliver revenues in excess of $220 million in 2022. Marc N. Casper, Chairman, President, and CEO of Thermo Fisher commented, "This transaction perfectly aligns with our Mission and is an exciting addition to our existing specialty diagnostic offerings.
8 stocks to watch for Monday: Ford, Thermo Fisher, China names and more (NYSE:F) 2022/10/31 12:29:02 Seeking Alpha
Ford (F), Emerson Electric (EMR), Thermo Fisher (TMO), XPeng (XPEV), Li Auto (LI), Alibaba (BABA), JD.com (JD) and Baidu (BIDU) are among the stocks to watch on Monday.
Thermo Fisher to buy diagnostics firm Binding Site for $2.6 bln 2022/10/31 12:17:21 Financial Post
Thermo Fisher Scientific Inc said on Monday it would buy Binding Site Group from European private equity firm Nordic Capital in an all-cash transaction valued at 2.25 billion pounds ($2.6 billion), boosting its specialty diagnostics business. Birmingham, U.K.-based Binding Site’s test helps detect and monitor multiple myeloma, a cancer in a type of white blood […]
Thermo Fisher Scientific America Signs 8 Year PPA for Half of Its Electricity Needs 2022/09/30 00:23:50 Environment+Energy Leader
Thermo Fisher Scientific signed an eight-year virtual power purchasing agreement with Enel North America to deliver a 90-megawatt (MW) portion of the Seven Cowboy wind project in western Oklahoma The post Thermo Fisher Scientific America Signs 8 Year PPA for Half of Its Electricity Needs appeared first on Environment + Energy Leader .
Thermo Fisher wins FDA OK of Oncomine Dx Target test to aid in cancer therapy selection 2022/09/27 21:04:58 Seeking Alpha
The US FDA has granted approval to Thermo Fisher Scientific''s (TMO) Oncomine Dx Target test to help determine which cancer patients may benefit from Eli Lilly’s (LLY)…
7 Profitable Places to Hide Your Money as We Enter a Bear Market 2022/09/27 14:00:38 InvestorPlace
Source: Ruslan Ivantsov / Shutterstock.com Wall Street has officially entered a bear market. Macroeconomic headwinds continue to build, including rampant inflation, slowing economic growth and continued geopolitical turmoil. We now have further uncertainty surrounding the stock market following the most recent interest rate hike. As we enter a bear market, investors are searching for alternative investment paths for diversification. Growth names that were the darlings on Wall Street during the pandemic have not been immune to these challenges so far in the year. Even large-capitalization (cap) shares have come under pressure since January. Year-to-date (YTD), the S&P 500 index has so far dropped over 22.9% year-to-date (YTD), while the tech-heavy Nasdaq 100 has declined more than 30.7% during the same period. In the past century, we have had over 25 bear markets on the Street. Most have lasted an average of less than one year. While it may be tempting to sell stocks in the portfolio to minimize losses, panic selling in a bear market often leads to loss of potential profits and even investment capital.
Molecular Diagnostics Market to Reach US$ 37.19 Bn by 2028, TMR Study 2022/09/26 12:33:00 Accesswire
WILMINGTON, DE / ACCESSWIRE / September 26, 2022 / Transparency Market Research Inc. - Rising use of automation in various healthcare and biotech research processes is creating attractive opportunities in the global molecular diagnostics market . This trend is further bolstered by the rising need for incorporating automation for facilitating various processes, including extraction of DNA, amplification, and analyzing and recording healthcare data. These automated systems offer various benefits, such as higher efficiency, precise output, and reduced time required for gaining results. Based on a recent research report, the global molecular diagnostics market is estimated to rise at a CAGR of 11.1% over the forecast period of 2021 to 2028. Get Exclusive PDF Sample Copy of Molecular Diagnostics Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1783 Growing adoption of molecular diagnostic devices in various diagnostic laboratories, biotech and pharma companies, hospitals, and research and academic institutes is creating growth opportunities for players in the global molecular diagnostics market in developed economies.
Thermo Fisher Scientific Inc – Consensus Indicates Potential 26.8% Upside 2022/09/25 11:45:00 DirectorsTalk
Thermo Fisher Scientific Inc with ticker code (TMO) now have 22 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 715 and 525 with a mean TP of 659.91. Now with the previous closing price of 520.29 this would indicate that there is a potential upside of 26.8%. There is a 50 day moving average of 567.14 while the 200 day moving average is 570.34. The market capitalisation for the company is $204,040m. Company Website: https://www.thermofisher.com [stock_market_widget type="chart" template="basic" color="green" assets="TMO" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $258,794m based on the market concensus. Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company''s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.